We have compiled a list of acquisitions of immunotherapy stocks that were publicly-traded on the New York Stock Exchange and NASDAQ Exchange. The buyouts of these biotechnology stocks ranged in value from $300 million to $74 billion. The companies associated with these stocks were developing immunotherapies for cancer, autoimmune diseases, infectious diseases, and more.
Access our full list of 140+ ImmunoBiotech companies, catalyst timeline, and immunotherapy drug database on the ImmunoBiotech Viewspace. Note that the table can be sorted by clicking on headings and searched using the search bar.
Learn about the latest news from the ImmunoBiotech space.